See more : Beijer Ref AB (publ) (BEIJ-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Inotiv, Inc. (NOTV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inotiv, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- HAZ Holdings, Inc. (HAZH) Income Statement Analysis – Financial Results
- Jiangsu Zhongchao Holding Co., Ltd. (002471.SZ) Income Statement Analysis – Financial Results
- Geox S.p.A. (GXSBF) Income Statement Analysis – Financial Results
- Perella Weinberg Partners (PWPPW) Income Statement Analysis – Financial Results
- Adler Modemärkte AG (ADD.DE) Income Statement Analysis – Financial Results
Inotiv, Inc. (NOTV)
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.74M | 572.43M | 547.66M | 89.61M | 60.47M | 43.62M | 26.35M | 24.24M | 20.44M | 22.70M | 24.58M | 22.07M | 28.21M | 33.14M | 28.78M | 31.78M | 41.70M | 45.25M | 43.05M | 42.40M | 37.15M | 29.84M | 26.51M | 25.27M | 19.22M | 19.90M | 18.20M | 14.90M |
| Cost of Revenue | 379.57M | 406.98M | 390.44M | 59.45M | 42.23M | 30.70M | 18.23M | 16.55M | 16.02M | 15.21M | 16.62M | 15.01M | 21.37M | 22.64M | 21.45M | 24.18M | 26.36M | 31.45M | 29.24M | 27.05M | 25.62M | 19.43M | 15.95M | 13.15M | 10.58M | 9.20M | 7.60M | 5.80M |
| Gross Profit | 111.17M | 165.44M | 157.21M | 30.16M | 18.24M | 12.92M | 8.12M | 7.70M | 4.43M | 7.49M | 7.96M | 7.06M | 6.84M | 10.51M | 7.33M | 7.60M | 15.33M | 13.79M | 13.81M | 15.34M | 11.53M | 10.41M | 10.56M | 12.12M | 8.64M | 10.70M | 10.60M | 9.10M |
| Gross Profit Ratio | 22.65% | 28.90% | 28.71% | 33.65% | 30.16% | 29.62% | 30.81% | 31.75% | 21.65% | 32.99% | 32.39% | 31.97% | 24.24% | 31.70% | 25.48% | 23.92% | 36.77% | 30.48% | 32.08% | 36.19% | 31.05% | 34.89% | 39.84% | 47.95% | 44.95% | 53.77% | 58.24% | 61.07% |
| Research & Development | 0.00 | 0.00 | 0.00 | 405.00K | 950.00K | 627.00K | 596.00K | 465.00K | 496.00K | 715.00K | 658.00K | 454.00K | 542.00K | 534.00K | 546.00K | 762.00K | 781.00K | 881.00K | 1.44M | 1.33M | 1.10M | 1.33M | 1.52M | 1.61M | 1.81M | 2.00M | 2.20M | 1.60M |
| General & Administrative | 77.03M | 108.23M | 82.44M | 30.38M | 16.98M | 9.53M | 5.97M | 4.90M | 4.58M | 5.07M | 4.94M | 4.41M | 5.52M | 5.56M | 6.12M | 7.67M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Selling & Marketing | 20.88M | 19.09M | 16.65M | 3.52M | 3.37M | 2.91M | 1.54M | 1.05M | 1.42M | 1.40M | 1.66M | 1.37M | 3.26M | 3.12M | 2.67M | 3.30M | 3.91M | 2.78M | 0.00 | 0.00 | 0.00 | 2.85B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 97.92M | 127.32M | 99.09M | 33.89M | 20.35M | 12.45M | 7.51M | 5.95M | 6.00M | 6.47M | 6.60M | 5.77M | 8.79M | 8.69M | 8.78M | 10.97M | 11.73M | 10.43M | 14.73M | 12.78M | 10.18M | 8.28M | 7.42M | 7.02M | 6.39M | 6.50M | 6.80M | 5.90M |
| Other Expenses | 99.66M | 119.59M | 85.57M | 1.48M | 15.00K | 9.00K | 6.00K | 5.00K | 6.00K | 5.00K | 9.00K | 7.00K | 12.00K | 0.00 | 0.00 | 472.00K | 24.00K | 92.00K | 1.06M | -21.43K | 0.00 | 0.00 | 0.00 | 0.00 | 1.64M | 1.30M | 900.00K | 500.00K |
| Operating Expenses | 197.58M | 246.90M | 184.66M | 35.77M | 21.30M | 13.07M | 8.10M | 6.42M | 6.49M | 7.19M | 7.25M | 6.23M | 9.33M | 9.22M | 9.33M | 11.73M | 12.54M | 11.40M | 17.23M | 14.08M | 11.28M | 9.61M | 8.94M | 8.63M | 9.83M | 9.80M | 9.90M | 8.00M |
| Cost & Expenses | 577.15M | 653.89M | 575.10M | 95.22M | 63.53M | 43.77M | 26.33M | 22.96M | 22.51M | 22.39M | 23.88M | 21.24M | 30.70M | 31.86M | 30.78M | 35.91M | 38.90M | 42.86M | 46.47M | 41.14M | 36.90M | 29.04M | 24.89M | 21.78M | 20.42M | 19.00M | 17.50M | 13.80M |
| Interest Income | 0.00 | 0.00 | 29.70M | 1.68M | 1.49M | 642.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 46.88M | 43.02M | 29.70M | 1.68M | 1.49M | 642.00K | 274.00K | 375.00K | 399.00K | 287.00K | 488.00K | 649.00K | 714.00K | 706.00K | 1.03M | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 57.12M | 54.72M | 49.32M | 7.56M | 4.98M | 2.72M | 1.86M | 1.68M | 1.56M | 1.41M | 1.60M | 1.72M | 2.28M | 2.13M | 2.32M | 2.65M | 3.01M | 3.46M | 3.89M | 3.44M | 3.44M | 2.68M | 2.04M | 1.76M | 1.64M | 1.30M | 900.00K | 500.00K |
| EBITDA | -26.76M | -26.51M | -273.42M | 15.37M | 1.03M | 2.57M | 1.88M | 2.96M | -1.29M | 1.71M | 1.02M | 2.55M | -3.40M | 3.43M | 327.00K | -1.95M | 5.81M | 2.39M | 366.00K | 4.72M | 3.67M | 3.48M | 3.67M | 5.25M | 444.11K | 2.20M | 1.60M | 1.60M |
| EBITDA Ratio | -5.45% | -4.63% | -6.83% | 8.71% | -5.04% | -0.33% | 0.08% | 5.29% | -10.09% | 1.36% | 9.41% | 3.79% | -8.79% | 10.32% | 1.13% | -4.66% | 13.97% | 13.12% | 3.53% | 11.04% | 9.75% | 10.07% | 13.38% | 20.67% | 2.74% | 10.55% | 8.24% | 10.74% |
| Operating Income | -86.41M | -81.46M | -27.45M | 1.53M | -3.06M | -153.00K | 14.00K | 1.28M | -3.04M | 909.00K | 334.00K | 830.00K | -5.69M | 1.29M | -2.00M | -4.60M | 2.79M | 2.39M | -3.42M | 1.26M | 254.00K | 800.00K | 1.63M | 3.49M | -1.19M | 900.00K | 700.00K | 1.10M |
| Operating Income Ratio | -17.61% | -14.23% | -5.01% | 1.71% | -5.07% | -0.35% | 0.05% | 5.27% | -14.87% | 4.00% | 1.36% | 3.76% | -20.16% | 3.88% | -6.94% | -14.47% | 6.70% | 5.28% | -7.95% | 2.97% | 0.68% | 2.68% | 6.14% | 13.81% | -6.20% | 4.52% | 3.85% | 7.38% |
| Total Other Income/Expenses | -44.35M | -42.78M | -89.00M | 501.00K | -1.48M | -633.00K | -268.00K | -370.00K | -204.00K | 205.00K | -1.40M | -41.00K | -702.00K | -694.00K | -1.03M | -1.06M | -971.00K | -891.00K | -2.67M | -933.00K | -832.29K | -229.00K | -79.29K | -383.49K | -621.01K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -130.76M | -124.24M | -352.45M | 6.12M | -4.54M | -786.00K | -254.00K | 908.00K | -3.24M | 1.11M | -1.06M | 789.00K | -6.39M | 593.00K | -3.02M | -5.66M | 1.82M | 1.50M | -4.44M | 291.39K | -607.00K | 570.58K | 1.55M | 3.11M | -1.81M | 900.00K | 700.00K | 1.10M |
| Income Before Tax Ratio | -26.65% | -21.70% | -64.36% | 6.83% | -7.50% | -1.80% | -0.96% | 3.75% | -15.87% | 4.91% | -4.32% | 3.58% | -22.65% | 1.79% | -10.51% | -17.81% | 4.37% | 3.31% | -10.30% | 0.69% | -1.63% | 1.91% | 5.84% | 12.29% | -9.43% | 4.52% | 3.85% | 7.38% |
| Income Tax Expense | -21.88M | -19.34M | -15.19M | -4.78M | 147.00K | 4.00K | -60.00K | 24.00K | -14.00K | 25.00K | 7.00K | 16.00K | 2.00K | 50.00K | -333.00K | -197.00K | 1.33M | 573.00K | -1.83M | 392.39K | -403.00K | 483.27K | 480.99K | 1.34M | -431.30K | 300.00K | 300.00K | 400.00K |
| Net Income | -108.45M | -105.14M | -337.26M | 10.90M | -4.69M | -790.00K | -194.00K | 884.00K | -3.23M | 1.09M | -1.07M | 773.00K | -6.39M | 543.00K | -2.69M | -5.46M | -1.49M | 926.00K | -2.61M | -101.00K | -203.00K | 87.31K | 1.07M | 1.77M | -1.38M | 600.00K | 400.00K | 700.00K |
| Net Income Ratio | -22.10% | -18.37% | -61.58% | 12.16% | -7.75% | -1.81% | -0.74% | 3.65% | -15.80% | 4.80% | -4.35% | 3.50% | -22.65% | 1.64% | -9.35% | -17.19% | -3.57% | 2.05% | -6.06% | -0.24% | -0.55% | 0.29% | 4.02% | 6.99% | -7.19% | 3.02% | 2.20% | 4.70% |
| EPS | -5.89 | -4.10 | -13.85 | 0.83 | -0.43 | -0.08 | -0.02 | 0.11 | -0.40 | 0.14 | -0.13 | 0.10 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.39 | -0.30 | 0.13 | 0.10 | 0.30 |
| EPS Diluted | -5.89 | -4.10 | -13.85 | 0.79 | -0.43 | -0.08 | -0.02 | 0.10 | -0.40 | 0.07 | -0.13 | 0.09 | -0.89 | -0.74 | -0.55 | -1.11 | -0.30 | 0.19 | -0.53 | -0.02 | -0.04 | 0.01 | 0.23 | 0.38 | -0.30 | 0.12 | 0.09 | 0.21 |
| Weighted Avg Shares Out | 25.90M | 25.64M | 24.35M | 13.19M | 10.85M | 10.38M | 8.77M | 8.18M | 8.11M | 8.08M | 7.96M | 7.66M | 7.16M | 5.67M | 4.92M | 4.92M | 4.91M | 4.91M | 4.88M | 4.87M | 4.86M | 4.66M | 4.58M | 4.56M | 4.55M | 4.51M | 4.12M | 4.39M |
| Weighted Avg Shares Out (Dil) | 25.90M | 25.64M | 24.35M | 13.87M | 10.85M | 10.38M | 8.77M | 8.73M | 8.11M | 8.79M | 7.96M | 8.37M | 7.16M | 5.67M | 4.92M | 4.92M | 4.97M | 4.96M | 4.88M | 4.87M | 4.86M | 4.67M | 4.63M | 4.60M | 4.55M | 4.68M | 4.40M | 4.39M |
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
INOTIV ALERT: Bragar Eagel & Squire, P.C. is Investigating Inotiv, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Inotiv: The Business Is Recovering, The Stock Will Follow
Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock
Inotiv, Inc. (NOTV) Q4 2023 Earnings Call Transcript
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
Inotiv, Inc. Announces Plan to Insource North American Transportation Operations
Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023
Inotiv Provides Business Updates and Upcoming Investor Conferences Update
Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
Source: https://incomestatements.info
Category: Stock Reports